Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAALAD2 | Q9Y3Q0 | 3/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.46 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.46 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.40 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.39 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.38 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.37 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23499736 | 0.86 | NAALAD2 (0.52) | NAALAD2FOLH1ENPEPGABRR1CYP1A2 | |
| SCHEMBL23499629 | 0.83 | NAALAD2 (0.50) | NAALAD2FOLH1ENPEPGABRR1CYP1A2 | |
| SCHEMBL443229 | 0.80 | NAALAD2 (0.56) | NAALAD2FOLH1ENPEPGABRR1CYP1A2 | |
| SCHEMBL10938417 | 0.80 | NAALAD2 (0.56) | NAALAD2FOLH1ENPEPGABRR1CYP1A2 | |
| SCHEMBL7314519 | 0.80 | NAALAD2 (0.56) | NAALAD2FOLH1ENPEPGABRR1CYP1A2 | |
| SCHEMBL9272361 | 0.79 | NAALAD2 (0.46) | NAALAD2FOLH1ENPEPGABRR1CYP1A2 | |
| SCHEMBL4213397 | 0.79 | RNPEP (0.48) | NAALAD2FOLH1ENPEPGABRR1CYP1A2 | |
| SCHEMBL9550634 | 0.79 | NAALAD2 (0.46) | NAALAD2FOLH1ENPEPGABRR1CYP1A2 | |
| SCHEMBL1572858 | 0.79 | NAALAD2 (0.46) | NAALAD2FOLH1ENPEPGABRR1CYP1A2 | |
| SCHEMBL61073 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | RAYZEBIO, INC. | 2023-05-25 | — | — | US | disclosed |
| EP-2788326-B1 | N-(PYRID-4-YL)AMIDES AND N-(PYRIMIDIN-4-YL)AMIDES AND THEIR PHARMACEUTICAL AND COSMETIC USE | GALDERMA RES & DEV (FR) | 2019-04-24 | — | — | EP | disclosed |
| EP-3029131-A1 | PRODUCTION METHOD FOR COMPOSITE POLYESTER COMPOSITION, COMPOSITE POLYESTER COMPOSITION, LUBRICANT COMPOSITION, AND LUBRICANT | Fujifilm Corporation (JP) | 2016-06-08 | — | — | EP | disclosed |
| WO-2011008232-A2 | BIOSYNTHETIC ROUTES TO LONG-CHAIN a, w-HYDROXY ACIDS, DIACIDS AND THEIR CONVERSION TO OLIGOMERS AND POLYMERS | DNA 2.0 INC. (US) | 2011-01-20 | — | — | WO | disclosed |
| US-7414155-B2 | Process for the hydroformylation of an ethylenically unsaturated compound | SHELL OIL COMPANY (US) | 2008-08-19 | — | — | US | disclosed |
| EP-1542798-B1 | PROCESS FOR THE HYDROFORMYLATION OF AN ETHYLENICALLY UNSATURATED COMPOUND USING A BIDENTATE DIPHOSPHINE COMPOSITION WITH A BRIDGING GROUP COMPRISING SP2 HYBRIDIZED CARBON ATOMS BOUND TO THE PHOSPHOROUS ATOMS | SHELL INT RESEARCH (NL) | 2007-11-14 | — | — | EP | disclosed |
| US-20070238892-A1 | PROCESS FOR THE HYDROFORMYLATION OF AN ETHYLENICALLY UNSATURATED COMPOUND | DRENT EIT | 2007-10-11 | — | — | US | disclosed |
| US-7250538-B2 | Process for the hydroformylation of an ethylenically unsaturated compound | SHELL OIL COMPANY (US) | 2007-07-31 | — | — | US | disclosed |
| EP-1542798-A2 | PROCESS FOR THE HYDROFORMYLATION OF AN ETHYLENICALLY UNSATURATED COMPOUND USING A BIDENTATE DIPHOSPHINE COMPOSITION WITH A BRIDGING GROUP COMPRISING SP2 HYBRIDIZED CARBON ATOMS BOUND TO THE PHOSPHOROUS ATOMS | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 2005-06-22 | — | — | EP | disclosed |
| US-20040167362-A1 | Process for the hydroformylation of an ethylenically unsaturated compound | SHELL OIL COMPANY | 2004-08-26 | — | — | US | disclosed |
| WO-2004028689-A2 | PROCESS FOR THE HYDROFORMYLATION OF AN ETHYLENICALLY UNSATURATED COMPOUND USING A BIDENTATE DIPHOSPHINE COMPOSITION WITH A BRIDGING GROUP COMPRISING SP2 HYBRIDIZED CARBON ATOMS BOUND TO THE PHOSPHOROUS ATOMS | SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V. (NL) | 2004-04-08 | — | — | WO | disclosed |
| US-5155237-A | Heating low molecular weight polylactones in presence of alkali metal, ammonium or phosphonium cations | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-10-13 | — | — | US | disclosed |
| EP-0408255-A1 | Thermoplastic resin composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1991-01-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | PAICS, LNPEP, DNPEP | NAALAD2 459/4885FOLH1 6/4885ENPEP 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.